Abstract #LBA4005

StageII／III結腸癌に対する補助化学療法としてのFULVとFULV + oxaliplatinと比較する第III相試験：NSABP　C-07試験

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

N. Wolmark，et al.

Abstract #4006

Stage II-III結腸癌患者に対する術後補助化学療法としてのmFOLFOX6 + bevacizumab (BV)とmFOLFOX6の無作為化第III相試験における安全性の報告：NSABP C-08試験

Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer.

C. J. Allegra，et al.

Abstract #4007

結腸癌に対する細胞障害性補助療法を施行された患者における再発からのOSと3年DFSの関連：20,898例のACCENTデータセットからの知見

Association between 3-year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,898 patient (pt) ACCENT dataset.

A. de Gramont, for the Adjuvant Colon Cancer Endpoints (ACCENT) Group

Abstract #4010

転移を有する結腸・直腸癌に対するoxaliplatinの間歇的投与法とTTF：第III相試験CONcePT試験の最終結果

Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial

A. Grothey，et al.

Abstract #LBA4011

進行結腸・直腸癌に対するcapecitabine+oxaliplatin+bevacizumab±cetuximab療法の無作為化第III相試験（CAIRO2試験）

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG).

C. J. Punt，et al.

Abstract #4012

大腸癌切除不能肝転移に対する化学療法併用ラジオ波焼灼術の無作為化第II相試験の中間報告：EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)

Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).

T. Ruers，et al.

Abstract #LBA4013

結腸・直腸癌肝転移に対する治癒切除後の補助化学療法：LV5FUs vs FOLFIRIの無作為化第III相試験（CPT-GMA-301試験）

Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FUs) versus LV5FU + irinotecan (LV5FU + IRI) as adjubant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301)

M. Ychou，et al.